Mounjaro 2.5 mg (Tirzepatide) 2.5 mg/0.5 mL
Mounjaro 2.5 mg (Tirzepatide 2.5 mg) is a breakthrough, first-in-class medication for type 2 diabetes and chronic weight management.
Manufacturer: Eli Lilly (India). Unlike other injectable weight-loss drugs that target only one hormone, Mounjaro targets two.
Mechanism of Action ("Dual GIP/GLP-1 Agonist"):
Tirzepatide activates receptors for both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). This synergistic effect enhances insulin secretion, suppresses glucagon levels, slows gastric emptying, and significantly reduces appetite. It essentially "reprograms" the body's metabolic set point.
✅ Key Benefit: Superior weight loss and A1C reduction compared to GLP-1 receptor agonists alone.
Indicated for adults with:
- 🍬 Type 2 Diabetes Mellitus: To improve glycemic control.
- ⚖️ Chronic Weight Management: For patients with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with weight-related comorbidities.
Packaging: Single-dose Vial (2.5 mg / 0.5 ml).
⚠️ DOSAGE PROTOCOL (Initiation):
- 💉 2.5 mg Dose: This is the starting dose used for the first 4 weeks to allow the body to adjust. It is not considered a therapeutic dose for glycemic control.
- 📅 Frequency: Inject subcutaneously once weekly, on the same day each week.
- 📍 Sites: Abdomen, thigh, or upper arm. Rotate injection sites.
- Personal or family history of Medullary Thyroid Carcinoma (MTC).
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Known hypersensitivity to Tirzepatide.
- Pregnancy and breastfeeding.
Gastrointestinal side effects are common during dose escalation:
- 🤢 Digestive: Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia.
- ⚠️ Pancreatitis: Severe abdominal pain radiating to the back (rare but serious).
- Hypoglycemia (when used with insulin).
Similar products
What Customers Say
No reviews yet
Your review can be the first!